Loading
The PD-L1 antibody avelumab cured about half of women whose gestational trophoblastic tumour had stopped responding to single-drug chemotherapy, with mild side effects.
Single-arm phase 2 trial at the Hospices Civils de Lyon: 15 women with gestational trophoblastic tumours resistant to methotrexate (all) or actinomycin D received avelumab 10 mg/kg every two weeks until hCG normalised and for three further cycles.
Eight women (53.3 percent) reached normal hCG after a median of nine cycles and none relapsed at a median follow-up of 25 months; one later had a healthy pregnancy. Grade 1 to 2 treatment-related adverse events occurred in 93 percent (fatigue, nausea or vomiting, infusion reactions); the seven non-responders were cured with actinomycin D or combination chemotherapy and surgery.
Avelumab is a chemotherapy-sparing option for single-agent-resistant gestational trophoblastic neoplasia, particularly where the alternative is combination chemotherapy.
Shares Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6), Journal of Clinical Oncology.
Shares Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6), Gestational trophoblastic neoplasia, Avelumab.
Shares Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6), Gestational trophoblastic neoplasia.
Shares Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6), Gestational trophoblastic neoplasia.